Determination of Plasma Concentration of Harmine Derivative DH- 330 by UPLC-MS and Its Pharmacokinetics Ev aluation in Rats
- VernacularTitle:超高效液相色谱-串联质谱法测定去氢骆驼蓬碱衍生物DH-330血药浓度及其在大鼠体内的药动学评价
- Author:
Huijing GAO
1
;
Ahmat ARSLAN
2
;
Zhaohui XU
3
;
Wenxi FAN
3
;
Guoru CHEN
4
;
Jun ZHAO
1
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of Xinjiang Medical University，Urumqi 830054，China
2. Xinjiang Institute for Food and Drug Control，Urumqi 830002，China
3. Xinjiang Huashidan Pharmaceutical Co.，Ltd.，Urumqi 830011，China
4. College of P harmacy，Xinjiang Medical University，Urumqi 830011，China
- Publication Type:Journal Article
- Keywords:
Harmine derivative;
DH-330;
UPLC-MS;
Plasma concentration;
Pharmacokinetics;
Rats
- From:
China Pharmacy
2019;30(12):1590-1594
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE： To establish a method for the determination of harmine derivative DH-330 in rat plasma and to use it for pharmacokinetic behavior evaluation of DH-330 in rats after intragastric administration. METHODS： Using tinidazole as internal standard， after pre-treatment of acetonitrile precipitated protein， UPLC-MS method was adopted to determine the plasma concentration of DH-330. UPLC analysis was performed on Waters ACQUITY BEH C18 column （50 mm×2.1 mm，1.7 μm） with mobile phase consisted of acetonitrile-methanol-0.5％ formic acid aqueous solution（15 ∶ 55 ∶ 30， V/V/V） at flow rate of 0.4 mL/min， while the column temperature was 30 ℃， and sample size was 5 μL. MS analysis was conducted by electrospray ionization source， positive ion scanning， ion source temperature at 124 ℃， DH-330 detection of mass to charge ratio （m/z） of 335.8→334.8， and internal standard m/z of 247.0→81.0. Six Wistar rats were given DH-330 suspension（50 mg/kg） intragastrically. Blood samples were collected from fundus venous plexus capillary before administration （0 h） and 0.25，0.5，1，2，4，6，8，12，24 h after administration. Plasma concentration of DH-330 was determined and plasma concentration-time curves were drawn. Pharmacokinetic parameters were calculated by using Kinetica 5.0 software. RESULTS： The linear ranges of DH-330 were 25.05-2 004 ng/mL（r＝0.999 8），and the limits of quantitation was 25.05 ng/mL. RSDs of intra-day and inter-day were all less than 10％. The accuracy RE was －9.76％ to 4.55％. The extraction recovery was higher than 85％（RSD＜5％）. Stability RE was －2.53％ to 2.29％. They were not affected by matrix effect or residual effect of injection. The pharmacokinetic parameters of DH-330 in rats after intragastric administration included that cmax was （1 162.43±241.72）ng/mL，AUC0-∞ was （3 242.93±652.31）ng·h/mL，t1/2 was （1.93±0.61）h， MRT was （3.23±0.30）h，CL was （16.80±5.30）L/h·kg， Vss was （54.78±19.64）L/kg. CONCLUSIONS： The established method is simple， specific， sensitive， precise and recovery， which can be used for the plasma concentration determination of DH-330 in rats. DH-330 has short half-life， rapid absorption and large apparent distribution volume after intragastric administration in rats， which indicates that it has high lipophilicity and may be mainly distributed in tissues.
